The pCPA released the completed list of products negotiated by December 31, 2017.
The next step towards gaining access to this therapy is for the provinces drug plan managers to implement the conditions of the LOI within their province. This process can take a few of weeks to a number of months depending on their budgets or formulary cycle.
Although the process has been lengthy, we’re very pleased that our voices were heard thanks to our collective advocacy efforts. Kyprolis® is now entering the last phase of the reimbursement process, which will ultimately provide Canadian patients access to this important therapy in the near future.
*A letter of intent (LOI) is a document which outlines the agreed upon terms and conditions for listing a drug on provincial formularies